Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
Medtronic
Moodys
Federal Trade Commission
Accenture
Cerilliant
Johnson and Johnson
Express Scripts

Generated: July 15, 2018

DrugPatentWatch Database Preview

VRAYLAR Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Vraylar patents expire, and what generic alternatives are available?

Vraylar is a drug marketed by Allergan Sales Llc and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-nine patent family members in thirty-six countries.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cariprazine hydrochloride profile page.
Summary for VRAYLAR
Drug patent expirations by year for VRAYLAR
Generic Entry Opportunity Date for VRAYLAR
Generic Entry Date for VRAYLAR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VRAYLAR
Synonyms for VRAYLAR
1083076-69-0
3-((1R,4r)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea hydrochloride
AK341028
AKOS027338713
Cariprazine (hydrochloride)
Cariprazine HCl
CARIPRAZINE HYDROCHLORIDE
Cariprazine hydrochloride (JAN/USAN)
Cariprazine hydrochloride [USAN]
cariprazine monohydrochloride
cariprazine.HCl
CHEBI:90932
CHEMBL2024517
CS-1570
D09876
EX-A1644
FT-0701196
HY-14763A
KQD7C255YG
KS-00000640
MFCD26142670
MolPort-044-723-876
N'-(Trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-N,N-dimthylurea monohydrochloride
N'-(trans-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexyl)-N,N-dimethylurea hydrochloride
RGH-188 HCL
SCHEMBL183803
SCHEMBL183804
UNII-KQD7C255YG
Urea, N'-(trans-4-(2-(4-(2,3-dichlorophenyl)-1-piperazinyl)ethyl)cyclohexyl)-N,N- dimethyl-, hydrochloride (1:1)
Vraylar (TN)

US Patents and Regulatory Information for VRAYLAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-001 Sep 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-002 Sep 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-001 Sep 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-003 Sep 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for VRAYLAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0913 Netherlands ➤ Sign Up PRODUCT NAME: CARIPRAZINE, OPTIONEEL IN DE VORM VAN EEN ZOUT, WAARONDER CARIPRAZINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/17/1209 20170717
2017 00042 Denmark ➤ Sign Up PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; REG. NO/DATE: EU/1/17/1209 20170717
/2017 Austria ➤ Sign Up PRODUCT NAME: CARIPRAZIN, GEGEBENENFALLS IN FORM EINES SALZES, EINSCHLIESSLICH CARIPRAZIN HYDROCHLORID; REGISTRATION NO/DATE: EU/1/17/1209 (MITTEILUNG) 20170717
2017000083 Germany ➤ Sign Up PRODUCT NAME: CARIPRAZIN, GEGEBENENFALLS IN FORM EINES SALZES, EINSCHLIESSLICH CARIPRAZINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/17/1209 20170713
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Healthtrust
Federal Trade Commission
US Department of Justice
Deloitte
Cerilliant
US Army
UBS
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.